Canadian Centre on Substance Use and Addiction Evidence. Engagement. Impact.
Canadian Centre on Substance Use and Addiction

The information on COVID-19 and substance use in this section comes from resource collections, academic publications, policies and guides from the federal, provincial and territorial governments as well as professional organizations.

CCSA cannot vouch for the accuracy or currency of the information in these resources. Inclusion of a resource on this page does not imply endorsement or authorization by CCSA.

Policies and Guidelines

Policies and Guidelines

Resource Organization
CDSA Exemption and Interpretive Guide for Controlled Substances Health Canada
Exceptional importation & sale of drugs in relation to COVID-19: Tier 3 drug shortages Health Canada
Frequently Asked Questions: Subsection 56(1) Class Exemption for Patients, Practitioners and Pharmacists Prescribing and Providing Controlled Substances in Canada during the Coronavirus Pandemic Health Canada
Provincial/Territorial Class Exemptions for Supervised Consumption Site Operators Health Canada
Subsection 56(1) class exemption for patients, practitioners and pharmacists prescribing and providing controlled substances in Canada during the coronavirus pandemic Health Canada
In the time of COVID-19: Civil society statement on COVID-19 and people who use drugs International Drug Policy Consortium
Statement by the UN expert on the right to health on the protection of people who use drugs during the COVID-19 pandemic Office of the High Commissioner of Human Rights, United Nations
COVID-19 Guidance: Consumption and Treatment Services (CTS) Sites  Ontario Ministry of Health
COVID-19: Information for Opioid Agonist Treatment Prescribers and Pharmacists  British Columbia Centre on Substance Use
Opioid Stewardship Under the New CDSA Exemptions (webinar) Canadian Pharmacists Association
Supporting people who use substances in acute care settings during the COVID-19 pandemic Canadian Research Initiative on Substance Misuse
Medications and other clinical approaches to support physical distancing for people who use substances during the COVID-19 pandemic Canadian Research Initiative on Substance Misuse
Strategies to Reduce SARS-CoV-2 Transmission in Supportive Recovery Programs and Residential Addiction Treatment Services Canadian Research Initiative on Substance Misuse
Harm reduction worker safety during the COVID-19 global pandemic Canadian Research Initiative on Substance Misuse
Early Guidance for Pharmacists in Managing Opioid Agonist Treatment during the COVID-19 Pandemic Centre for Addiction and Mental Health
Frequently Asked Questions: Subsection 56(1) Class Exemption for Patients, Practitioners and Pharmacists Prescribing and Providing Controlled Substances in Canada during the Coronavirus Pandemic Health Canada
CDSA Exemption and Interpretive Guide for Controlled Substances Health Canada
Clinical guide for the management of people with alcohol dependence during the coronavirus pandemic National Health Service, England
A public health approach to withdrawal management in a pandemic Vancouver Coastal Health
Prescriber Guidelines for Risk Mitigation in the Context of Dual Public Health Emergencies Vancouver Coastal Health
Le traitement du trouble lié à l’utilisation d’opioïdes (TUO) (in French only) Collège des médecins du Québec
La pharmacothérapie de remplacement des substances psychoactives dans le contexte de pandémie de COVID-19 au Québec: Guide clinique à l’intention des prescripteurs (in French only) Institut universitaire sur les dépendances (IUD) du CIUSSS du Centre-Sud-de-l’Île-de-Montréal

 

We use cookies to ensure that we give you the best experience possible on our website. 

You can change your cookie settings in your web browser at any time. If you continue without changing your settings, we’ll assume that you are happy to receive cookies from our website. Review our Privacy Notice for more information.